Discovery is the ultimate industry partner for academic, government, and non-profit researchers. We provide access to the world’s largest commercial biobank, the most advanced technology platforms, and multi-omic experts so you can achieve breakthroughs faster and keep pace with the high demands for resources and advanced technologies.
Discovery offers a full spectrum of human biospecimens to support academic, government, and non-profit research in oncology, infectious disease, autoimmune disease, metabolic disorders, cardiology, neurology, and more. Below are a few of the many biospecimen types offered by Discovery:
Discovery’s multi-omic biomarker services are customizable, scalable, and flexible. We help our partners become nimbler and gain access to innovative and advanced technologies.
Reliable and customizable proteomic services from multiplexed immunoassay such as Olink to mass spectrometry enabling improved understanding of real-time human biology.
Discovery Genomics is one of the largest commercial genomic service labs that offers high-throughput whole genome, exome, transcriptomic, targeted, single cell, and epigenetic sequencing services powered by advanced bioinformatics.
Discovery is a 10X Genomics Center of Excellence and offers a range of single cell analyses, including CITE-Seq, ATAC-Seq, and Visium spatial gene expression analysis.
Pathologist-driven, GCLP-compliant procedures for developing and validating AI-driven digital image analysis and custom IHC/mIF assays in CAP-accredited and CLIA-certified GCLP compliant laboratories.
We have extensive experience aligning project priorities with cutting-edge technologies and valuable resources, so you can overcome challenges and achieve your goals faster.
Discovery has tested over 23,500 unique samples for the NIH-funded GMKF project focused on utilizing high- throughput deep sequencing of DNA and RNA to help uncover new insights in childhood cancer and structural birth defects.
Chosen as the very first sequencing center by the NIH All of Us program to leverage long-read whole genome sequencing technologies to generate genetic data on ~2,000 participants from diverse backgrounds
Discovery has supported major government-funded projects, including NIH’s Gabriella Miller Kids First and All of Us programs. We have tested over 50,000 NGS samples for ongoing government collaborations.
With our extensive experience in aligning government priorities with cutting-edge technologies and resources, Discovery is dedicated to assisting our biopharma partners in maximizing their chances of winning government-funded projects.
Dr. Aisha Mergaert will be attending the ASH Annual Meeting to support her co-authored poster with Solu Therapeutics on December 8 from 6-8 PM at the San Diego Convention Center, […]
Join Discovery at Advanced Therapies Week 2025.
Join Discovery at Precision Medicine Tri-Con 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
